What is the catalog number for PF-06447475?

The catalog number for PF-06447475 is HY-12477.

What sizes are available for PF-06447475?

PF-06447475 is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg.

How many pack sizes does PF-06447475 come in?

PF-06447475 is available in 7 different pack sizes.

Is PF-06447475 in stock?

PF-06447475 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures PF-06447475?

PF-06447475 is manufactured by QuantiMol.

What is the estimated delivery time for PF-06447475?

Estimated delivery time for PF-06447475 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for PF-06447475?

The safety data sheet for PF-06447475 is available here: http://file.medchemexpress.com/batch_PDF/HY-12477/PF-06447475-SDS-MedChemExpress.pdf.

PF-06447475

PF-06447475 is a highly potent, selective and brain penetrant LRRK2 inhibitor with an IC50 of 3 nM.

Product Specifications

CAS Number

1527473-33-1

UNSPSC

12352005

Hazard Statement

H301

Target

LRRK2

Type

Reference compound

Related Pathways

Autophagy

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/PF-06447475.html

Purity

99.94

Solubility

DMSO : 60 mg/mL (ultrasonic)

Smiles

N#CC1=CC=CC(C2=CNC3=NC=NC(N4CCOCC4)=C32)=C1

Molecular Formula

C17H15N5O

Molecular Weight

305.33

Precautions

H301

References & Citations

[1]Henderson JL, et al. Discovery and preclinical profiling of 3-[4- (morpholin-4-yl) -7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58 (1) :419-32.|[2]Mendivil-Perez M, et al. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease. Neurochem Res. 2016 Oct;41 (10) :2675-2692.|[3]Daher JP, et al. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. J Biol Chem. 2015 Aug 7;290 (32) :19433-44.